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ABSTRACT
Background: We have previously shown that short-course treatment with Amb a 1-immunostimulatory phos-
phorothioate oligonucleotide conjugate (AIC) before the ragweed season modifies the response of the nasal
mucosa to allergen challenge in ragweed-sensitive patients by increasing Th1 cytokines and decreasing both
Th2 cytokines and eosinophilia after the ragweed season. The effect of AIC immunotherapy on CD4+CD25+ T
cell expression in the nasal mucosa is unknown.
Objective: To determine the in vivo effect of short-course AIC immunotherapy on CD4+CD25+ regulatory T
cells in the nasal mucosa of ragweed-sensitive subjects.
Methods: 19 ragweed-sensitive patients with allergic rhinitis were randomly assigned to receive either 6 esca-
lating doses of AIC (0.06―12 μg; n = 12) or placebo (n = 7) at weekly intervals immediately before the 2001 rag-
weed season. Nasal biopsies were taken at baseline prior to immunization and again post immunization 24
hours after ragweed allergen challenge at the start and end of the ragweed season. The expression of T regu-
latory cells, IL-10 and TGF-β was assessed at each time point by immunohistochemistry.
Results: The numbers of allergen-induced CD4+-, CD4+CD25+-, IL-10- and TGF-β-positive cells in the nasal
mucosa after AIC immunization before the ragweed season did not differ between the two groups. Repeat chal-
lenge after the ragweed season led to a significant increase in CD4+CD25+ cells in AIC-compared with
placebo-treated subjects. A trend toward an increase in IL-10-positive cells in the AIC-treated group did not
reach statistical significance.
Conclusions: Short-course AIC immunotherapy increases CD4+CD25+ regulatory T cell infiltration in the na-
sal mucosa following allergen challenge after seasonal ragweed-pollen exposure.
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ABBREVIATIONS
AIC, Amb a 1-immunostimulatory phosphorothioate oligonucleotide conjugate; ISS, immunostimulatory DNA
sequences; TLR, toll-like receptor; PAMP, pathogen associated molecular pattern; pDC, plasmacytoid dendritic
cells; TGF-β, transforming growth factor beta; APAAP, alkaline phosphatase-anti-alkaline phosphatase
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INTRODUCTION
A Th2-dominant immune imbalance exists in the im-
mune response of allergic patients and this is thought
to be a main target for intervention. Allergen immu-
notherapy represents a therapeutic option for patients
with IgE-mediated allergic rhinitis whose seasonal
symptoms are not adequately controlled by allergen
avoidance and symptomatic pharmacological treat-
ments. Allergen-specific immunotherapy aims to
modify this immune imbalance particularly by at-
tempting to redirect the established Th2-dominated
response toward more balanced Th1Th2 re-
sponses.1,2 Considerable attention has been focused
on the development of more novel immunotherapies
that are safer and have shorter treatment regimens
than conventional allergen-specific immunotherapy.
The use of toll-like receptor (TLR) ligands in com-
bination with allergens to modify the function of anti-
gen presenting cells has been proposed as a new
strategy for biasing the immune response toward Th1
in allergic disease. Amb a 1-immunostimulatory phos-
phorothioate oligonucleotide conjugate (AIC) one
such novel compound, has received a lot of attention
in recent years and has lately undergone large multi-
center phase 23 clinical trials with encouraging
short- and long-term clinical results in subjects with
moderate-to-severe ragweed allergy.3 It is produced
by covalently linking the purified short ragweed pol-
len allergen, Amb a 1 conjugate, to a phos-
phorothioate oligodeoxyribonucleotide immunosti-
mulatory sequence (ISS-ODN) containing a CpG mo-
tif. The ISS is a short synthetic DNA sequence that
binds to TLR9 on plasmacytoid dendritic cells (pDC)
with subsequent activation of the innate immune sys-
tem.4 Due to the enhanced immunogenicity and re-
duced allergenic properties of AIC compared with
Amb a 1 alone, this vaccine has potential as a novel
form of immunotherapy with a shorter treatment regi-
men and higher doses for subjects with allergy to rag-
weed pollen.5
The mechanisms by which AIC modulates the im-
mune response are currently the focus of many stud-
ies. We have previously reported that short-course
AIC immunotherapy before the ragweed season
modifies the response of the nasal mucosa to allergen
challenge in ragweed-sensitive patients and causes a
significant increase in the number of IFN-γ mRNA-
positive cells with concomitant decreases in both IL-4
mRNA-positive cells and eosinophilia in nasal biop-
sies of ragweed-sensitive patients after the ragweed
season compared with placebo-treated patients.6 Si-
mons et al. demonstrated a similar biasing of the im-
mune response towards Th1 in primary peripheral
blood mononuclear cells from patients with ragweed
allergy cultured for a short time with AIC.7
Suppression of the Th2 response by AIC therapy
may occur through the induction of a subtype of T
cell with immunosuppressive functions called regula-
tory T cells. These CD4+CD25+ T-cells with regula-
tory function have a specific cytokine profile produc-
ing both IL-10 and TGF-β and are known to suppress
inflammation in both normal and atopic patients.8,9
Conventional allergen-specific immunotherapy in-
duces a population of IL-10-producing CD4+CD25+
regulatory T cells in the peripheral blood of atopic pa-
tients following in vitro allergen restimulation.10 Re-
cently, it has been demonstrated that CpG-activated
human pDCs induce CD4+CD25+FoxP3+ regulatory T
cells that suppress antigen-stimulated T-cell prolifera-
tion in vitro.11 However, the in vivo effect of AIC im-
munotherapy on CD4+CD25+ T regulatory cell ex-
pression in the nasal mucosa is currently unknown.
The aim of this study was to evaluate the presence
of CD4+CD25+ regulatory T cells in the nasal mucosa
of ragweed-sensitive patients with allergic rhinitis be-
fore and after short-course AIC immunotherapy and
to also assess the expression of their suppressive cy-
tokines, IL-10 and TGF-β, in these tissues.
METHODS
SUBJECT RECRUITMENT
19 subjects with known ragweed allergy and a history
of symptomatic seasonal rhino-conjunctivitis who
gave their written informed consent to have nasal bi-
opsies taken at 3 different time points were included.
Many of these subjects demonstrated at least one
positive skin prick test response to other allergens
suggesting that they were not monosensitized to rag-
weed. 12 subjects received AIC and 7 age- and sex-
matched subjects received placebo. All patients were
immunotherapy naïve prior to enrollment. These sub-
jects represent a subgroup of a previous larger
study.6 The study was reviewed and approved by IRB
Services (Toronto) and the Comité d’évaluation Sci-
entifique et d’éthique de la Recherche, Hôpital Saint-
Luc (CHUM).
STUDY DESIGN SAMPLE COLLECTION
A baseline nasal biopsy was performed on all 19 par-
ticipating subjects without prior allergen challenge or
immunization. Ragweed sensitivity was confirmed in
all subjects by nasal challenge with ragweed antigen
extract as previously described.6 Subjects were ran-
domized in an observer-blinded fashion to receive
either 6 escalating doses of AIC (0.06, 0.3, 1.2, 3.0,
6.0, and 12.0 μg; n = 12) or placebo (n = 7) by subcu-
taneous injection at weekly intervals ending 2 to 4
weeks before the 2001 ragweed season. AIC was pre-
pared as previously published.5 A second nasal bi-
opsy was taken 24 hours after ragweed allergen chal-
lenge at the start of the ragweed season and a third
biopsy was taken 1 to 2 months after the end of the
ragweed season.
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Fig. 1 Graphs showing the number of cels that immu-
nostained positively for CD4＋CD25＋ in nasal biopsies of 
AIC-treated and placebo-treated subjects with alergic rhini-
tis at baseline, before and after the alergen season.
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Fig. 2 (A) Representative examples of immunohisto-
chemistry of bronchial biopsies showing staining for IL-10 in 
a subject treatment with AIC. Positive immunostaining was 
obtained by using the alkaline phosphatase-antialkaline 
phosphatase method. Magnification ×200. (B) Graphs 
showing the number of cels that immunostained positively 
for IL-10 in nasal biopsies of AIC-treated and placebo-
treated subjects with alergic rhinitis at baseline, before and 
after the alergen season.
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NASAL CHALLENGE AND BIOPSY
Prior to the initiation of immunotherapy, all subjects
underwent a nasal challenge with ragweed antigen
extract (3.59 AU; Greer Laboratories, Lenoir, NC).
This was performed by applying a filter paper disk
soaked in allergen or diluent (0.4% phenol preserved
saline) and applied unilaterally to the inferior tur-
binate for 60 seconds, as previously described.12 A
positive response to ragweed was defined as 3 or
more sneezes than experienced with diluent chal-
lenge. Patients consenting to serial biopsies were
challenged at 24 hours before the biopsy at the time
points of 2 weeks after the last injection of AIC or pla-
cebo and 1 to 2 months after the end of the 2001 rag-
weed season as described above. Nasal biopsy speci-
mens measured 2 mm in diameter and were taken
from the posterior portion of the anterior third of the
inferior turbinate of the nasal mucosa. Alternate nos-
trils were used for subsequent biopsies. Biopsy speci-
mens were immediately mounted in OCT compound
(VWR; Ville Mont-Royal, Quebec, Canada), snap-
frozen by means of immersion in isopentane, pre-
cooled in liquid nitrogen and stored at −80℃ until
processing.
IMMUNOHISTOCHEMISTRY
The expression of T regulatory cells, CD4, IL-10 and
TGF-β was assessed at each time point by immuno-
histochemistry on 5-μm cryostat sections fixed in 4%
paraformaldehyde. Double staining for CD4 and CD
25 was used to identify CD4+CD25+ regulatory T
cells. Briefly, tissue sections were incubated with the
appropriate primary antibody or isotype-matched con-
trol. Slides were washed in TBS and incubated with
secondary antibody. The peroxidase method was em-
ployed to immunostain for CD25 which was devel-
oped with diaminobenzidine-chromogen (Dako Can-
ada Inc., Mississauga, Ontario, Canada). The alkaline
phosphatase-anti-alkaline phosphatase (APAAP) tech-
nique was used for all other immunostaining. Coun-
terstaining was performed with haematoxylin.
Immunoreactive positive cells were counted in the
submucosa by two blinded independent observers us-
ing an Olympus light microscope (Carson Group Inc.,
Markham, Ontario, Canada) at 200× magnification
with an eyepiece graticule of 0.202 mm2. The average
number of positive cells was calculated from 2 to 4
random, non-overlapping grids and expressed as the
mean number of positive cells per millimeter square.
STATISTICS
Results are expressed as means ± SEMs. Statistical
analyses were performed using non-parametric tests.
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Fig. 3 Graphs showing the number of cels that immu-
nostained positively for TGF-β in nasal biopsies of AIC-
treated and placebo-treated subjects with alergic rhinitis at 
baseline, before and after the alergen season.
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Fig. 4 (A) Representative examples of immunohistochemistry 
of bronchial biopsies showing staining for IL-10 in a subject 
treated with AIC. Positive immunostaining was obtained by 
using the alkaline phosphatase-antialkaline phosphatase 
method. (B) Graph showing the number of immunoreactive 
cels for CD4＋ in nasal biopsies of AIC-treated and placebo-
treated subjects with alergic rhinitis at baseline, before and 
after the alergen season.
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Comparisons between treatment groups were made
using the Fisher exact test for proportions and the
Wilcoxon 2-sample test for continuous variables.
Comparisons within treatment groups were made us-
ing the Friedman test followed by the Wilcoxon
signed-rank test. All statistical tests were 2-tailed and
a P value of <0.05 was considered to indicate a statisti-
cally significant difference.
RESULTS
19 subjects fulfilled the criteria and consented to hav-
ing nasal biopsies taken at all 3 time points. 12 sub-
jects were randomized to receive AIC and 7 age- and
sex-matched subjects received placebo.
The numbers of allergen-induced CD4+-, CD4+
CD25+-, IL-10- and TGF-β-positive cells present in the
nasal mucosa after AIC immunization and before the
ragweed season did not differ from the placebo-
treated group at the same time point or from baseline
numbers. Following repeat challenge after the end of
the ragweed season, AIC-treated patients showed a
significant increase in CD4+CD25+ cells compared
with placebo-treated patients (p < 0.01) and compared
with baseline nasal biopsies (p < 0.05) (Fig. 1). A
trend toward an increase in IL-10-positive cells in the
AIC-treated group post-season compared with both
placebo-treated and baseline biopsies did not reach
statistical significance (p = 0.08, Fig. 2B). A similar
trend was noted for TGF-β in the AIC-treated group
(p = 0.09, Fig. 3). There was no difference noted in
CD4+ cell numbers in the nasal biopsies taken at the
start and end of the ragweed season in either treat-
ment group (Fig. 4).
DISCUSSION
AIC immunotherapy ensures that both ISS and Amb
a 1 antigen are presented simultaneously to the same
immune cells, producing a highly specific and potent
inhibitory effect and thereby suppressing the Th2
cells responsible for the allergic inflammation of rag-
weed allergy. CpG ODNs stimulate cells that express
TLR9, thereby initiating an immunomodulatory cas-
cade that culminates in the production of Th1 and
pro-inflammatory cytokines and chemokines. In addi-
tion, they improve the antigen-presenting function of
DCs, monocytes and macrophages, recruit T cells to
the site of ODN administration and induce B cell pro-
liferation.
The generation of allergen-specific regulatory T-
cells and increased production of their suppressive
cytokines, IL-10 and TGF-β, are essential early events
in allergen specific immunotherapy.8,9 IL-10 is a po-
tent suppressor of both total and allergen-specific IgE
and simultaneously increases IgG4 production.13 This
CpG Vaccines in Allergic Rhinitis
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ultimately leads to a decrease in IgE-mediated hista-
mine release. In addition, IL-10 reduces pro-
inflammatory cytokine release from mast cells, down-
regulates eosinophil function and activity and sup-
presses IL-5 production by Th0 and Th2 cells.14
In our previous report which includes the same
subjects as in the present study, we demonstrated
that AIC treatment reduced mRNA expression of IL-4
and IL-5 after the ragweed season.6 These phenom-
ena might be mediated by increase in CD4+CD25+
cells via inhibition of proliferation and cytokine pro-
duction on Th1 and Th2.9 In contrast, mRNA expres-
sion of INF-γ was increased in our previous report.6
However, the effects of CD4+CD25+ cells on expres-
sion of INF-γ are different depending on the re-
port.9,11 Increase in CD4+ CD25+ cells and its derived
IL-10 may be involved in the anti-inflammatory effects
of AIC immunization. However, further studies are
needed to clarify these mechanisms.
Macrophages and B cells also have the potential to
express IL-10 following AIC immunotherapy. IL-10
produced by macrophages is a key modulator of im-
mune tolerance in immunotherapy. In our study, the
IL-10-positive cells were morphologically mononu-
clear cells. However, we did not perform IL-10+ CD4+
CD25+ triple immunostaining.
In this study we have shown for the first time that
AIC, a CpG-conjugate allergen immunotherapy, in-
creases CD4+CD25+ T-cell infiltration of the nasal mu-
cosa following allergen challenge. We have also
shown a strong trend toward an increase in IL-10
positive cells in the nasal mucosa following allergen
challenge.
CpG vaccines that target TLR9 show encouraging
results to date in the treatment of allergic disease.
We have shown that AIC immunotherapy modifies
the immune response in the nasal mucosa following
allergen challenge after seasonal ragweed-pollen ex-
posure via the induction of T regulatory cells. Further
experiments aimed at clarifying the exact mechanism
of action of these compounds are required.
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